Integrin alpha(5)beta(1) is expressed on activated endothelial cells and plays a critical role in
tumor angiogenesis. We hypothesized that a novel
integrin alpha(5)beta(1) antagonist,
ATN-161, would inhibit angiogenesis and growth of liver
metastases in a murine model. We further hypothesized that combining
ATN-161 with
5-fluorouracil (5-FU)
chemotherapy would enhance the
antineoplastic effect. Murine
colon cancer cells (CT26) were injected into spleens of BALB/c mice to produce liver
metastases. Four days thereafter, mice were given either
ATN-161 (100 mg/kg, every 3rd day) or saline by
intraperitoneal injection, with or without combination of continuous-infusion
5-FU (100 mg/kg/2 weeks), which was started on day 7. On day 20 after
tumor cell inoculation, mice were killed and liver weights and number of liver
metastases were determined. A follow-up study on survival was also conducted in which mice were randomized to receive
ATN-161,
5-FU or ATN-161+5-FU. Combination
therapy with ATN-161+5-FU significantly reduced
tumor burden (liver weight) and number of liver
metastases (p<0.02). Liver
tumors in the
ATN-161 and ATN-161+5-FU groups had significantly fewer microvessels (p<0.05) than
tumors in the control or 5-FU-treated groups. Unlike treatment with either agent alone, ATN-161+5-FU significantly increased
tumor cell apoptosis and decreased
tumor cell proliferation (p<0.03) and improved overall survival (p<0.03, log-rank test). Targeting
integrin alpha(5)beta(1) in combination with
5-FU infusion reduced liver
metastases formation and improved survival in this
colon cancer model. The enhancement of
antineoplastic activity from the combination of anti-angiogenic
therapy and
chemotherapy may be a promising approach for treating metastatic
colorectal cancer.